Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Uveal Melanoma 1Noonan Syndrome 6 1Melanoma 1

Interventions

pembrolizumab 58Cyclophosphamide 53Ipilimumab 52Nivolumab 44aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 18dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11Filgrastim 10Dacarbazine 10spartalizumab 9cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × entrectinib × Dermatologic × Clear all
NCT04589832 2023-11-22

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Hoosier Cancer Research Network

Phase 1/2 Terminated
6 enrolled 9 charts
Dermatologic

Uveal Melanoma

NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

University of California, San Francisco

Phase 2 Terminated
1 enrolled 7 charts
Dermatologic

Noonan Syndrome 6, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡